Journal article
PD-L1 and Tumor infiltrating lymphocytes as prognostic markers in resected NSCLC
M Ameratunga, K Asadi, X Lin, M Walkiewicz, C Murone, S Knight, P Mitchell, P Boutros, T John
Plos One | PUBLIC LIBRARY SCIENCE | Published : 2016
Open access
Abstract
Introduction Immune checkpoint inhibition has shifted treatment paradigms in non-small cell lung cancer (NSCLC). Conflicting results have been reported regarding the immune infiltrate and programmed death-ligand 1 (PD-L1) as a prognostic marker. We correlated the immune infiltrate and PD-L1 expression with clinicopathologic characteristics in a cohort of resected NSCLC. Methods A tissue microarray was constructed using triplicate cores from consecutive resected NSCLC. Immunohistochemistry was performed for CD8, FOXP3 and PD-L1. Strong PD-L1 expression was predefined as greater than 50% tumor cell positivity. Matched nodal samples were assessed for concordance of PD-L1 expression. Results Of ..
View full abstractGrants
Funding Acknowledgements
Thomas John received funding from the National Health and Medical Research Council (NHMRC). This study was conducted with the support of the Ontario Institute for Cancer Research to PCB through funding provided by the Government of Ontario. Dr. Boutros was supported by a Terry Fox Research Institute New Investigator Award and by a Canadian Institutes of Health Research (CIHR) New Investigator Award. The Victorian Cancer Biobank is supported by the Victorian Government. Assoc Prof John is an NHMRC Early Career Scholar and receives funding from the Cancer Council Victoria. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.